Post by cGxP.wire

📢 Gan & Lee Pharmaceuticals Showcases Metabolic Pipeline Data at ADA 2026 🔗 Read more: https://lnkd.in/gM4WPZAq Gan & Lee Pharmaceuticals presented new metabolic disease pipeline data at #ADA2026, highlighting progress across its development programs. About the Company: • Gan & Lee Pharmaceuticals is a leading #biopharmaceutical company focused on metabolic diseases • Dedicated to advancing innovative therapies for diabetes and obesity About the Presentation: • New pipeline data presented at ADA 2026 • Focused on metabolic health innovation • Demonstrated ongoing R&D progress Key Highlights: • ADA 2026 scientific presentation • Expanding metabolic disease pipeline • Advances innovation in diabetes care "Congratulations to the Gan & Lee Pharmaceuticals team on sharing these important developments." 🎉 都凯, 邢程, Spencer Carter, Maria Diaz Genovese 🤝 “Continued investment in metabolic research is helping shape the future of healthcare.” #ADA2026 #MetabolicHealth #DiabetesCare #Biopharma #HealthcareInnovation #ClinicalResearch FDA The National Institutes of Health Centers for Disease Control and Prevention ISO - International Organization for Standardization World Health Organization European Medicines Agency American Diabetes Association European Association for the Study of Diabetes International Diabetes Federation Endocrine Society The Obesity Society World Obesity Federation American Association of Clinical Endocrinology (AACE) || cGxP.wire || cGxP.Directory || cGxP.jobs || cGxP.Tech ||